Blogs

WHA70: Statement of Portugal on the Global shortage of, and access to medicines and vaccines

Portugal delivered the following statement at the 70th World Health Assembly on agenda item, 13.3 - Global shortage of, and access to medicines and vaccines.

PortugalWHA70.png

In relation to the Report of the United Nations High-Level Panel on Access to Medicines (UNHLP), the delegation of Portugal quoted the intervention delivered by the Portuguese Minister of Health, Professor Campos Fernandes at the plenary of the 70th World Health Assembly.

WHA70: Statement of Knowledge Ecology International - CEWG follow up

On Friday, 26 May 2017, Knowledge Ecology International delivered the following intervention on the Follow-up of the report of the Consultative Expert Working Group on Research and Development: Financing and Coordination. The statement was delivered by Thiru Balasubramaniam.

13.5 Follow-up of the report of the Consultative Expert Working Group on Research and Development: Financing and Coordination

Statement:

In May 2016, the 69th World Health Assembly (WHA) requested (WHA69.23) the Director-General:

WHA70: Statement of Knowledge Ecology International on antimicrobial resistance

On Wednesday, 24 May 2017, Knowledge Ecology International delivered the following intervention on antimicrobial resistance. This statement was read by Andrew Goldman.

KEI would like to call attention to a proposal introduced in the United States Congress, as Senate Bill 771, sponsored by 16 US Senators, and HR 1776, which has 14 sponsors in the House of Representatives.

SEC. 409K of the bill is titled, “PRIZE FUND FOR NEW AND MORE EFFECTIVE TREATMENTS OF BACTERIAL INFECTIONS.”

WHA70: Statement of Knowledge Ecology International on review of the GSPOA-PHI

On Friday, 26 May 2017, Knowledge Ecology International delivered the following intervention on the Evaluation and review of the global strategy and plan of action on public health, innovation and intellectual property. This statement was read by Manon Ress.

13.4 Evaluation and review of the global strategy and plan of action on public health, innovation and intellectual property

The GSPOA evaluation conducted by Capra International was disappointing, raising questions about the terms of reference, and low ambition.

WHA70: Statement of Knowledge Ecology International: Review of the Pandemic Influenza Preparedness Framework

On Thursday, 25 May 2017, Knowledge Ecology International (KEI) delivered the following intervention on the Review of the Pandemic Influenza Preparedness Framework (PIP) at the 70th session of the World Health Assembly (WHA).

WHA70: Statement of Knowledge Ecology International on Research and development for potentially epidemic diseases

On Wednesday, 24 May 2017, Knowledge Ecology International delivered its maiden statement to the World Health Assembly on the topic of research and development for potentially epidemic diseases. The intervention was read by Diane Singhroy, PhD.

Seventieth World Health Assembly (A70/1)
Agenda Item: 12.1.3 Research and development for potentially epidemic diseases

Rep. Jan Schakowsky Questions Dr. Anthony Fauci on Zika Vaccine Price at House Energy and Commerce Subcommittee Hearing

On May 23, 2017, Rep. Jan Schakowsky, D-Ill., asked Dr. Anthony Fauci whether he believed the federal government should use "every tool" to ensure that Sanofi charges a fair price for a taxpayer-funded Zika vaccine that is being developed by the U.S. Army and funded by BARDA.

Dr. Fauci responded that he did not believe that the government had the "mechanisms" to guarantee an affordable price, even when the U.S. government and taxpayers have made a "major investment" in the development of a drug.

KEI has separately uploaded a short clip of the exchange between Rep. Schakowsky and Dr. Fauci:

Additional information on the Army-BARDA-Sanofi vaccine collaboration is available at http://keionline.org/zika and http://keionline.org/zika-timeline.

Video of the full hearing and copies of written testimony are available via the House Energy and Commerce Committee website: https://energycommerce.house.gov/hearings-and-votes/hearings/us-public-health-response-zika-virus-continuing-challenges.

Groups ask Army to reconsider decision that would allow French firm to charge U.S. anything it wants on federally-funded vaccine

23 May 2017

Groups ask Army to reconsider decision that would allow French firm to charge the US anything it wants on a federally funded Zika vaccine

CONTACT: Zack Struver, zack.struver@keionline.org, +1 (914) 582-1428
Andrew Goldman, andrew.goldman@keionline.org
James Love, james.love@keionline.org, +1 (202) 361-3040

WHA70 - Side Event on Addressing Access Barriers and Affordability Challenges for Cancer Drugs - 24 May 2017

On Wednesday, 24 May 2017, Knowledge Ecology International (KEI), Oxfam and Stichting Health Action International (HAI) are convening a side event on addressing access barriers and affordability challenges for cancer medicines. This panel will take place in Salle IX of the United Nations Palais des Nations from 18:00 to 19:30.

Date: Wednesday, 24 May 2017
Time: 18:00 to 19:30
Location: Salle IX, United Nations Palais des Nations

Panelists:

Berlin Declaration of the G20 Health Ministers

After at least eight rounds of negotiation, including two Geneva-based negotiations held on 12 May 2017 and 17 May 2017, the G20 Health Ministers meeting, convened in Berlin from 19-20 May 2017 issued the following declaration.

In relation to the R&D pipeline for developing new antimicrobial therapies, the G20 recognized "the importance of fostering R&D for new antimicrobials, alternative therapies, vaccines and rapid-point-of care diagnostics, in particular for priority pathogens as identified by WHO and for tuberculosis."

Louisiana Governor John Bel Edwards Asks U.S. Army to Require Sanofi to Charge Reasonable Price for Zika Vaccine

The Louisiana Governor John Bel Edwards asked the U.S. Army to require Sanofi to charge a reasonable price for a taxpayer-funded Zika vaccine, in a letter dated May 10, 2017.

U.S. Army/Sanofi Zika Vaccine Collaboration Timeline and Update

Today I published a timeline on the collaboration between Sanofi and the U.S. Army regarding the development of a vaccine for the Zika virus.

One major issue that we have raised is on the price of the Zika Vaccine. KEI and other groups have asked the Army to ensure that Sanofi does not charge U.S. taxpayers a higher price than in other high-income countries. This is not a remote concern. Recently, we published a blog showing that Sanofi charges Americans four to eight times more for its MS drug Aubagio (teriflunomide) compared to other high-income countries. If Sanofi refuses to agree to a reasonable pricing provision, then we know that Sanofi wants to keep open the option of charging the United States the highest price in the world for a drug funded by American taxpayers.

The timeline provides the dates of several key events, such as the filing of patent applications, the dates of the Army/Sanofi CRADA and grants from BARDA, the signing of the Principles of Collaboration with the Oswaldo Cruz Foundation (Fiocruz), the publication of Federal Register notices on the intent of the Army to grant exclusive licenses on patents, responses by patient and public interest groups, the New York Times op-ed by Sen. Bernie Sanders and the response by Dr. Elias Zerhouni on behalf of Sanofi, and the letter from members of the House of Representatives.

KEI Comments for 70th World Health Assembly Listening Session at DHHS

Today KEI attended the annual listening session at DHHS, when speakers are alotted no more than 1.5 minutes to speak on a specific agenda item, with no more than two agenda items per speaker. Our brief comments were focused on advancing the delinkage approach in the contexts of the GSPOA, CEWG, and cancer.

Experts, NGOs ask WHA delegates to support feasibility study of funding cancer research without high prices

On May 3, 2017, 29 civil society organizations and 33 health professionals, activists, and economists — including Nobel Prize laureate Joseph Stiglitz — asked delegates to the World Health Assembly (WHA) to support a feasibility study on the progressive delinkage of the costs of research and development from the price of cancer medicines. The groups and experts sent a letter to the delegates.

KEI submission to OECD consultation on "Sustainable access to innovative therapies"

This was the KEI submission to the OECD consultation on "Sustainable access to innovative therapies," which involved four questions posed by OECD on access to medicines.

Question 1: Reflecting on the last 5-10 years, what do you think have been the major changes affecting access to medicines?

Syndicate content